Each year ~1.5 million American women between ages of 45 and 55 enter into the perimenopause. Yet to be discovered is the impact perimenopause has on key brain regions involved in cognition and known to be vulnerable to Alzheimer's disease (AD). Women have a higher lifetime risk of developing AD and represent more than 60% of the Alzheimer's disease population. The mission of our Perimenopause in Brain Aging and Alzheimer's Disease Program Project is to discover the biological transformations that occur in the brain during the perimenopausal transition that can result in phenotypes at risk for development of Alzheimer's pathology. We seek to identify the mechanisms by which these changes occur and to translate these discoveries to determine the optimal timing and strategies for preventing conversion to the perimenopausal at-AD-risk phenotype. To achieve our mission, we have developed a focused research center model with an integrated set of four Projects and three Cores. Projects 1, 2 and 3 are basic, mechanistic and preclinical translational science investigations of the perimenopausal brain utilizing our program developed rodent models of human perimenopause. Project 4 uses the results of Project 1, 2 and 3 to inform its ancillary association analysis of existing data and samples from the NIA-funded clinical trial Early versus Late Intervention Trial with Estrogen (ELITE) (R01AG-024154). To achieve our Program mission, each project has a unique but complementary research focus with all Aims of all projects and cores addressing Program wide aims. Innovative and integrative features of our Program include: bidirectional translational research;rodent models of human perimenopause transition;custom designed gene arrays that include GWAS identified AD risk factor genes and bioenergetic, inflammatory and AD system pathways, shared customized data and document management. Program-wide gene array and bioinformatic analyses across all projects. Discovery of at-AD-risk phenotypes and the underlying mechanisms of phenotype development could potentially lead to the early identification of those at greatest risk for developing AD and mechanistically inform interventions to prevent the disease. Program research addresses NIA Strategic Goals A and C.

Public Health Relevance

The Perimenopause in Brain Aging and Alzheimer's Disease Program Project will determine how the brain changes during the perimenopausal transition and how these changes can lead to development of early risk factors for developing Alzheimer's disease. The goal of these studies is the early identification of those at greatest risk for developing AD and the window of opportunity for interventions to prevent Alzheimer's disease in those at greatest risk postmenopausal women. REVIEW OF INDIVUDUAL COMPONENTS CORE A: ADMINISTRATIVE CORE;Dr. Roberta Brinton, Core Leader (CL). DESCRIPTION (provided by applicant): The mission of our Perimenopause in Brain Aging and Alzheimer's Disease Program Project is to discover the biological transformations that occur in the brain during the perimenopausal transition which can result in phenotypes predictive of risk for development of Alzheimer's pathology. We seek to identify the mechanisms by which these changes occur, and translate these discoveries to determine the optimal timing and strategies for preventing conversion to the perimenopausal at-risk phenotype. Successful execution of our Perimenopausal Program Project Aims demands a high degree of coordination, intellectual synergy, collaboration and communication across and among all Projects and Cores. Administrative Core provides a structural organization to facilitate timely and efficient communication and integrative links among Projects and Cores. The Administrative Core (Core A) will ensure the success of the Perimenopause Program Project through effective leadership, the provision of data management and biostatistical resources, and the forging of partnerships to synergize efforts and maximize resources. Administrative Core specific aims are: (1) Specific Aim 1: Lead and administer Perimenopause in Brain Aging and Alzheimer's Disease Program Project (manage and steward intellectual, technological and financial resources, identify and overcome barriers to progress, create liaisons with similarity-focused research and training programs);(2) Specific Aim 2: Provide organizational systems for data management and communication within the Program Project Members and External Reviewers (implement and maintain a Web-based data entry, data management, and animal- and specimen tracking system);(3) Specific Aim 3: Conduct program-wide integrated statistical and bioinformatic analysis (provide biostatistical consulting in the design, coordination, and analyses of projects, oversee gene array and bioinformatics data management on program data management system, integrate gene expression profile across program;conduct program-wide bioinformatics network analysis).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG026572-07
Application #
8336940
Study Section
Special Emphasis Panel (ZAG1-ZIJ-8 (02))
Program Officer
Wise, Bradley C
Project Start
2005-07-01
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2012
Total Cost
$1,727,202
Indirect Cost
$674,030
Name
University of Southern California
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Uchoa, Mariana F; Moser, V Alexandra; Pike, Christian J (2016) Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors. Front Neuroendocrinol 43:60-82
Yin, Fei; Sancheti, Harsh; Patil, Ishan et al. (2016) Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radic Biol Med 100:108-122
Finch, Caleb E; Shams, Sara (2016) Apolipoprotein E and Sex Bias in Cerebrovascular Aging of Men and Mice. Trends Neurosci 39:625-37
Cacciottolo, Mafalda; Christensen, Amy; Moser, Alexandra et al. (2016) The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. Neurobiol Aging 37:47-57
Rettberg, Jamaica R; Dang, Ha; Hodis, Howard N et al. (2016) Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype. Neurobiol Aging 40:155-63
Finch, Caleb E; Crimmins, Eileen M (2016) Constant molecular aging rates vs. the exponential acceleration of mortality. Proc Natl Acad Sci U S A 113:1121-3
Finch, Caleb E; McMahon, Andrew P (2016) Stem cells for all ages, yet hostage to aging. Stem Cell Investig 3:11
Karim, Roksana; Dang, Ha; Henderson, Victor W et al. (2016) Effect of Reproductive History and Exogenous Hormone Use on Cognitive Function in Mid- and Late Life. J Am Geriatr Soc 64:2448-2456
Wang, Yiwei; Brinton, Roberta D (2016) Triad of Risk for Late Onset Alzheimer's: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex. Front Aging Neurosci 8:232
Moser, V Alexandra; Pike, Christian J (2016) Obesity and sex interact in the regulation of Alzheimer's disease. Neurosci Biobehav Rev 67:102-18

Showing the most recent 10 out of 87 publications